CONSUN PHARMACEUTICAL GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.03 HKD | +1.01% |
|
+10.53% | +47.38% |
| May. 07 | Consun Pharmaceutical to Grant About 8.2 Million Share Options Under New Program | MT |
| Mar. 29 | Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.92 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +47.80% | 733M | - | ||
| +21.98% | 43.92B | B- | ||
| +23.33% | 23.09B | B+ | ||
| +19.25% | 15.35B | - | ||
| +14.03% | 13.61B | B+ | ||
| +46.40% | 12.02B | B | ||
| -9.98% | 7B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +13.88% | 5.6B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 1681 Stock
- Ratings Consun Pharmaceutical Group Limited
